Browsing by Subject "Atrial Fibrillation"

Adenosine-induced flow arrest to facilitate intracranial aneurysm clip ligation: dose-response data and safety profile.

Avram, MJ; Batjer, HH; Bebawy, JF; Bendok, BR; Gupta, Dhanesh K; Hemmer, LB; Koht, A; ... (8 authors) (Anesth Analg, 2010-05-01)

BACKGROUND: Adenosine-induced transient flow arrest has been used to facilitate clip ligation of intracranial aneurysms. However, the starting dose that is most likely to produce an adequate duration of profound hypotension ...

An adverse reaction to a medication given to treat an adverse reaction: a teachable moment.

Rohrhoff, NJ; McNeill, DB; Boggan, Joel (JAMA Intern Med, 2014-07)

Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Chang, P; Gersh, Bernard John; Holmqvist, Fredrik Nils; Hong, SJ; Kowey, Peter R; Naccarelli, GV; ORBIT-AF Investigators; ... (12 authors) (J Am Heart Assoc, 2015-05-21)

BACKGROUND: The characteristics of patients undergoing atrial fibrillation (AF) ablation and subsequent outcomes in community practice are not well described. METHODS AND RESULTS: Using the Outcomes Registry for Better Informed ...

Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya.

Akwanalo, CO; Bloomfield, Gerald; Chen, P-S; Emonyi, W; Heckbert, SR; Inui, TS; Kimaiyo, S; ... (16 authors) (PLoS One, 2017)

BACKGROUND: Atrial fibrillation (AF) is a major contributor to the global cardiovascular disease burden. The clinical profile and outcomes of AF patients with valvular heart diseases in sub-Saharan Africa (SSA) have not ...

Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya.

Akwanalo, CO; Bloomfield, Gerald; Chen, P-S; Emonyi, W; Heckbert, SR; Inui, TS; Kimaiyo, S; ... (16 authors) (PLoS One, 2017)

BACKGROUND: Atrial fibrillation (AF) is a major contributor to the global cardiovascular disease burden. The clinical profile and outcomes of AF patients with valvular heart diseases in sub-Saharan Africa (SSA) have not ...

Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?

Cao, L; Hayden, Kathleen M; Newby, Laura Kristin; Pokorney, SD; Welsh-Bohmer, Kathleen Anne (J Am Heart Assoc, 2015-08-03)

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, Bernard John; Holmes, DaJuanicia; Hylek, EM; ... (15 authors) (J Am Heart Assoc, 2013-11-25)

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...

Heart rate is associated with progression of atrial fibrillation, independent of rhythm.

Chang, P; Fonarow, GC; Freeman, JV; Gersh, Bernard John; Holmqvist, Fredrik Nils; Kim, S; Kowey, Peter R; ... (15 authors) (Heart, 2015-06)

OBJECTIVE: Atrial fibrillation (AF) often progresses from paroxysmal or persistent to more sustained forms, but the rate and predictors of AF progression in clinical practice are not well described. METHODS: Using the Outcomes ...

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF).

Chang, P; Fonarow, GC; Gersh, Bernard John; Holmqvist, Fredrik Nils; Hylek, E; Kim, S; Kowey, Peter R; ... (15 authors) (J Am Heart Assoc, 2015-09-14)

BACKGROUND: Most patients with atrial fibrillation (AF) require rate control; however, the optimal target heart rate remains under debate. We aimed to assess rate control and subsequent outcomes among patients with permanent ...

Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.

Fosbøl, Emil; Gersh, Bernard John; Holmes, DaJuanicia; Kowey, Peter R; Mahaffey, Kenneth William; Mills, RM; ORBIT-AF Investigators and Patients; ... (11 authors) (J Am Heart Assoc, 2013-07-18)

BACKGROUND: The prevalence of atrial fibrillation (AF) continues to increase; however, there are limited data describing the division of care among practitioners in the community and whether care differs depending on provider ...

Pulmonary vein isolation for the treatment of drug-refractory atrial fibrillation in adults with congenital heart disease.

Agarwal, S; Krasuski, Richard Andrew; Muhammad, KI; Natale, A; Philip, F (Congenit Heart Dis, 2012-07)

BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in adults with congenital heart disease (CHD). Long-term antiarrhythmic therapy (AAT) in these patients has significant shortcomings. The safety and efficacy of ...

Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure.

Fonarow, GC; Get With the Guidelines Steering Committee and Hospitals; Hernandez, Adrian Felipe; Liang, L; Peterson, Eric David; Piccini, Jonathan Paul Sr; Thomas, Kevin Lindsey; ... (8 authors) (J Am Heart Assoc, 2013-09-26)

BACKGROUND: The intersection of heart failure (HF) and atrial fibrillation (AF) is common, but the burden of AF among black patients with HF is poorly characterized. We sought to determine the prevalence of AF, characteristics, ...

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.

Arbetter, D; Bode, C; Burton, P; Chi, G; Cohen, M; Daaboul, Y; Fox, KAA; ... (19 authors) (Circulation, 2017-01-24)

BACKGROUND: Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of ...

Sex Differences in the Modifiable Risk Factors for Atrial Fibrillation at Moi Teaching and Referral Hospital

Ng'ang'a, Loise Mwihaki (2017)

Background: Evidence mainly from high-income countries has demonstrated sex related differences in the incidence, presentation and management of patients with non-valvular AF. Such evidence is scarce in sub-Saharan Africa, ...

Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry.

Chang, P; Fonarow, GC; Freeman, J; Gersh, Bernard John; Go, AS; Jackson, Larry Ronald II; Kim, SH; ... (14 authors) (Clin Cardiol, 2016-02)

BACKGROUND: Patients with sinus node dysfunction (SND) have increased risk of atrial tachyarrhythmias, including atrial fibrillation (AF). To date, treatment patterns and outcomes of patients with SND and AF have not been ...

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.

Ansell, JE; Chang, P; Fonarow, GC; Gersh, Bernard John; Hylek, EM; Kowey, Peter R; Mahaffey, Kenneth William; ... (13 authors) (Eur Heart J, 2015-12-07)

BACKGROUND: Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. OBJECTIVES: We sought to develop and validate a ...

Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Ansell, J; Chang, P; Fonarow, GC; Gersh, Bernard John; Kim, S; Kowey, Peter R; Mahaffey, Kenneth William; ... (13 authors) (Circulation, 2015-02-03)

BACKGROUND: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions ...